Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
Open Access
- 18 December 2020
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 24 (1), 3-10
- https://doi.org/10.1016/j.jval.2020.11.002
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Pasteur, The Netherlands
This publication has 31 references indexed in Scilit:
- The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort ModelPLOS ONE, 2014
- Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United StatesHuman Vaccines & Immunotherapeutics, 2014
- Integrating influenza antigenic dynamics with molecular evolutioneLife, 2014
- Dynamic Transmission ModelingMedical Decision Making, 2012
- Detection of Excess Influenza Severity: Associating Respiratory Hospitalization and Mortality Data With Reports of Influenza-Like Illness by Primary Care PhysiciansAmerican Journal of Public Health, 2010
- Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective AnalysisValue in Health, 2010
- Criteria for inclusion of vaccinations in public programmesVaccine, 2010
- Internet-based monitoring of influenza-like illness in the general population: Experience of five influenza seasons in the NetherlandsVaccine, 2009
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008
- Role of TLR1 and TLR6 in the host defense against disseminated candidiasisFEMS Immunology & Medical Microbiology, 2008